

# FIRST LINES AND LIFELINES: ANALGESIA AND SEDATION DURING DRUG SHORTAGES

---

NEIL ROE, PHARM.D, BCCCP

CLINICAL PHARMACY SPECIALIST – CRITICAL CARE

BAPTIST HEALTH MEDICAL CENTER, LITTLE ROCK, AR

# DISCLOSURE

---

I have no financial and/or commercial conflicts of interest to disclose.

**Disclaimer:** There is no substitute for identifying waste, good collaboration, or effective communication.

# OBJECTIVES

---

- Identify key concepts for analgesia and sedation in intensive care unit (ICU) patients
- Discuss first line and alternative pharmacotherapeutic agents
- Design a therapeutic regimen for a difficult ICU case

# CASE #1: RF

---

- 62 year old male
- PMH: Heavy EtOH use, HTN
- CC: Respiratory failure due to COVID19 pneumonia
- Mechanically ventilated


## CASE #2: CD

---

- 47 year old male
- History of methamphetamine use
- CC: Polysubstance ingestion, motor vehicle collision
- Intubated to protect airway

# PAIN

*“An unpleasant sensory and emotional experience associated with actual or potential tissue damage.”*



Complications	
Chronic pain	Stress
Sleep-loss	Hyper-metabolism
Impaired wound healing	Impaired immune function
Feelings of Helplessness	Post-traumatic stress disorder

# OPTIONS FOR PAIN

---

IV Opioids

- Acute non-neuropathic pain

Gabapentin / Pregabalin  
Carbamazepine

- Neuropathic pain

NSAIDS  
Acetaminophen  
Ketamine

- Adjunct treatments

# OPIOID ANALGESIA

---

- Aim for lowest effective dose
- Route will depend on clinical scenario
- Continuous infusions may be necessary
  - Used (almost) exclusively in ventilated patients
  - Drug accumulation can occur with prolonged infusions
  - Daily interruptions are beneficial



# OPIOID INFUSIONS — POSSIBLE DOSING

---

## PRIMARY

- Fentanyl 25-200 mcg/hr
- Hydromorphone 0.5-3 mg/hr

## SECONDARY / TERTIARY

- Morphine 2-30 mg/hr
- Remifentanyl 0.008-0.25 mcg/kg/min
- Sufentanyl 0.05-1 mcg/kg/hr

# STRATEGIES TO REDUCE OPIOIDS

---

- “Multi-modal” analgesia
  - Who should receive this?
- Acetaminophen up to 1g q6h (any route)
- Ketorolac or Ibuprofen in select patients
- Gabapentin, even as low as 300 mg/day
- Ketamine, 0.2-0.5 mg/kg IV bolus
  - If positive response, consider infusion at 1-2 mcg/kg/min

# STRATEGIES TO PROLONG OPIOID SUPPLY

---

- Flat rather than weight-based dosing
- Enteral opioid to supplement infusion
  - Functioning GI tract
  - Oxycodone 5-20 mg q4h
  - Likely best for those with lower opioid needs (fentanyl <150 mcg/hr)
- Transdermal fentanyl (1:1 IV to TD dosing)
  - Probably better than enteral if high opioid needs (>150 mcg/hr)
  - Wean infusion at 6, 8, and 10 hours after application
- Methadone to facilitate weaning
  - If on opioid infusion for prolonged duration (>7-10d)

# KETAMINE

---

- Blocks NMDA receptors in peripheral/central nervous system
- Activates mu and kappa opioid receptors
- Analgesic at lower doses (1-2 mcg/kg/min)
  - Can limit opioid tolerance and reduce requirements
- Sedative at higher doses (10-80 mcg/kg/min)
  - Produces dissociative sedation
- Pay attention to product concentrations

# METHADONE

---

- Consider in difficult to wean patients
- Dose considerations:
  - Incomplete cross-tolerance
  - Not aiming for equivalent dose
  - Long half life, steady state at 3-7 days
  - 10 mg q8h per tube may be a reasonable starting dose
- Weaning
  - Over 5-10 days
  - Decrease by 10-25% every 2-3 days
  - Stop when total daily dose <10-15 mg

# AGITATION

*“A syndrome of excessive motor activity, usually non-purposeful and associated with internal tension.”*



Photo: “Lumex Nightmare” by Ralph Sirianni

## SOURCES

Pain

Hypoxia

Withdrawal

Hypoglycemia

Delirium

Hypotension

# ASSESSMENT OF AGITATION

---

## **Richmond Agitation Sedation Scale (RASS)**

<b>Target RASS</b>	<b>RASS Description</b>
<b>+ 4</b>	Combative, violent, danger to staff
<b>+ 3</b>	Pulls or removes tube(s) or catheters; aggressive
<b>+ 2</b>	Frequent nonpurposeful movement, fights ventilator
<b>+ 1</b>	Anxious, apprehensive , but not aggressive
<b>0</b>	Alert and calm
<b>- 1</b>	awakens to voice (eye opening/contact) >10 sec
<b>- 2</b>	light sedation, briefly awakens to voice (eye opening/contact) <10 sec
<b>- 3</b>	moderate sedation, movement or eye opening. No eye contact
<b>- 4</b>	deep sedation, no response to voice, but movement or eye opening to physical stimulation
<b>- 5</b>	Unarousable, no response to voice or physical stimulation

# ASSESSMENT OF AGITATION

## Richmond Agitation Sedation Scale (RASS)

Target RASS	RASS Description	
+ 4	Sedation–Agitation Scale (SAS)	
+ 3	7	Dangerous agitation Pulling at ET tube, trying to remove catheters, climbing over bed rail, striking at staff, thrashing side-to-side
+ 2	6	Very agitated Does not calm, despite frequent verbal reminding of limits; requires physical restraints, biting ET tube
+ 1	5	Agitated Anxious or mildly agitated, attempting to sit up, calms down to verbal instructions
0	4	Calm and cooperative Calm, awakens easily, follows commands
- 1	3	Sedated Difficult to arouse, awakens to verbal stimuli or gentle shaking but drifts off again, follows simple commands
- 2	2	Very sedated Arouses to physical stimuli but does not communicate or follow commands, may move spontaneously
- 3	1	Unarousable Minimal or no response to noxious stimuli, does not communicate or follow commands
- 4		
- 5		



# KEYS TO SEDATION USE

---

## GOALS

- Patient comfort, safety
- Facilitate mechanical ventilation
- Facilitate neuromuscular blockade

## PRINCIPLES

- Lighter sedation is better
- Daily interruption is useful
- Non-benzodiazepines preferred

# OPTIONS FOR SEDATIVE INFUSIONS

---

## PRIMARY

Propofol 5-100 mcg/kg/min

Dexmedetomidine 0.1-1.5 mcg/kg/hr

## SECONDARY OR TERTIARY

Midazolam 1-10 mg/hr

Ketamine 10-80 mcg/kg/min

# OPTIONS FOR SEDATIVE INFUSIONS

	Midazolam	Propofol	Dexmedetomidine	Ketamine
Amnesia	X	X		X
Analgesia			X	X
Anticonvulsion	X	X		X
Antiemesis		X		
Anxiolysis	X	X		X
Hypnosis	X	X		X
Sedation	X	X	X	X
Bradycardia			X	
Hypotension	X	X	X	
Respiratory Depression	X	X		

# STRATEGIES TO REDUCE SEDATION USE

---

- Encourage lighter sedation
- Eliminate modifiable sources of agitation
  - Pain, hyponatremia, drug withdrawal
- Resume home neuropsychiatric meds
- Prevent delirium

# STRATEGIES TO PROLONG SEDATIVE SUPPLY

---

- Consider supplementing with enteral agent
  - Quetiapine, risperidone
  - Clonidine
  - Lorazepam, if already on benzodiazepine (up to 4 mg q4h)
- Adjunctive ketamine infusion

# NEUROMUSCULAR BLOCKADE (NMB)

---

- \* Deeper sedation levels needed prior to starting (RASS -4 to -5)
- Severe ARDS
  - Data initially showed possible mortality benefit (ACURASYS, NEJM 2010)
  - Recent study demonstrated no clinical benefit (PETAL, NEJM 2019)
- Impaired patient-ventilator synchrony
- Targeted temperature management

# OPTIONS FOR NMB INFUSIONS

---

## PRIMARY

Cisatracurium 0.5-10 mcg/kg/min

Vecuronium 0.8-1.7 mcg/kg/min

## SECONDARY OR TERTIARY

Rocuronium 4-16 mcg/kg/min

Atracurium 5-20 mcg/kg/min

### **Monitoring:**

- Physiologic parameters (skeletal muscle movement, spontaneous breathing, plateau pressures)
- Train of four devices (many limitations)

# STRATEGIES TO PROLONG NMB SUPPLY

---

- Attempt intermittent boluses first
  - Vecuronium 0.1-0.2 mg/kg
  - Rocuronium 0.6-1.2 mg/kg
  - Cisatracurium 0.1-0.2 mg/kg
- Daily release from NMB
- Educate providers on lack of benefit in recent ARDS trial
- Infusions >48 hours should be questioned



# CASE #1: RF

---

- 62 year old male
- PMH: Heavy EtOH use, HTN
- CC: Respiratory failure due to COVID19 pneumonia
- Mechanically ventilated

# CASE #1: RF

---

- 62 year old male
- CC: Respiratory failure due to COVID19 pneumonia
- **Day 2:**
  - Ventilator settings are increasing (FiO2 70% / PEEP 14)

**Pain:** Fentanyl 75 mcg/hr

**Sedation:** Propofol 50 mcg/kg/min

**NMB:** None

*Assume fentanyl and propofol shortage*

**Pain:** Start hydromorphone 0.5-3 mg/hr

**Sedation:** Start midazolam 2 mg IVP q10 min +  
infusion 1-10 mg/hr

**NMB:** None

# CASE #1: RF

---

- 62 year old male
- CC: Respiratory failure due to COVID19 pneumonia
- **Day 4:**
  - Pneumonia progresses to severe ARDS
  - Clinician wants neuromuscular blockade

*Assume fentanyl and propofol shortage*

**Pain:** Hydromorphone 1 mg/hr

**Sedation:** Midazolam 4 mg/hr → Bolus 2 mg and increase to 6 mg/hr for RASS -4

**NMB:** Vecuronium 0.2 mg/kg, if multiple doses needed within several hours, start drip 0.8-1.7 mcg/kg/min

# CASE #1: RF

---

- 62 year old male
- CC: Respiratory failure due to COVID19 pneumonia
- **Day 18:**
  - ARDS improved, attempts at ventilator weaning occur
  - Refractory agitation, discomfort occur when drips

*Assume fentanyl and propofol shortage*

**Pain:** Hydromorphone 3 mg/hr, add methadone 10 mg q8h per tube

**Sedation:** Dexmedetomidine 1.2 mcg/kg/min

**NMB:** Off

# CASE #1: RF

---

- 62 year old male
- CC: Respiratory failure due to COVID19 pneumonia
- **Day 20:**
  - Hydromorphone maintenance rate reduced
  - Hydromorphone turned off during awakening trial
  - Dexmedetomidine is maintained at low rate during breathing trial
  - Patient is able to be successfully extubated
  - Wean methadone over 5-10 days

*Assume fentanyl and propofol shortage*

**Pain:** Hydromorphone 1.5 mg/hr, methadone 10 mg q8h (day 3)

**Sedation:** Dexmedetomidine 1 mcg/kg/min

**NMB:** Off

# CASE #2: CD

---

- 47 year old male
- History of methamphetamine use
- CC: Polysubstance ingestion, motor vehicle collision
- **Day 1:**
  - Intubated to protect airway

**Pain:** Fentanyl 125 mcg/hr

**Sedation:** Propofol 60 mcg/kg/min

**NMB:** None

*Assume fentanyl and propofol shortage*

**Pain:** Start hydromorphone 0.5-3 mg/hr

**Sedation:** Dexmedetomidine 0.1-1.5 mcg/kg/hr

**NMB:** None

# CASE #2: CD

---

- 47 year old male
- History of methamphetamine use
- CC: Polysubstance ingestion, motor vehicle collision
- **Day 2:**
  - Intubated to protect airway
  - Consistently in pain, agitated, attempting to pull at lines/tubes

*Assume fentanyl and propofol shortage*

**Pain:** Hydromorphone 3 mg/hr, schedule APAP 1g q6h, Gabapentin 100 mg TID

**Sedation:** Dexmedetomidine 1.5 mcg/kg/hr, midazolam 4 mg/hr

**NMB:** None

# CASE #2: CD

---

- 47 year old male
- History of methamphetamine use
- CC: Polysubstance ingestion, motor vehicle collision
- **Day 3:**
  - Intubated to protect airway
  - Consistently in pain, agitated, attempting to pull at lines/tubes

*Assume fentanyl and propofol shortage*

**Pain:** Hydromorphone 3 mg/hr, schedule APAP 1g q6h, Gabapentin 100 mg TID

**Sedation:** Stop dexmedetomidine, add ketamine infusion, midazolam 4 mg/hr

**NMB:** None



# CASE #2: CD

---

- 47 year old male
- History of methamphetamine use
- CC: Polysubstance ingestion, motor vehicle collision
- **Day 5:**
  - Pain control much improved, less agitated
  - Ventilator weaning, ready for breathing trials

*Assume fentanyl and propofol shortage*

**Pain:** Hydromorphone 1 mg/hr, stop APAP, continue gabapentin

**Sedation:** Ketamine 20 mcg/kg/min

**NMB:** None

# CASE #2: CD

---

- 47 year old male
- History of methamphetamine use
- CC: Polysubstance ingestion, motor vehicle collision
- **Day 6:**
  - Awakening trial and breathing trial
  - Successfully extubated

*Assume fentanyl and propofol shortage*

**Pain:** HOLD hydromorphone infusion, stop APAP, continue gabapentin

**Sedation:** Drop ketamine to 1-2 mcg/kg/min, have PRN midazolam available

**NMB:** None

# FIRST LINES AND LIFELINES: ANALGESIA AND SEDATION DURING DRUG SHORTAGES

---

NEIL ROE, PHARM.D, BCCCP

CLINICAL PHARMACY SPECIALIST – CRITICAL CARE

BAPTIST HEALTH MEDICAL CENTER, LITTLE ROCK, AR